STOCK TITAN
  1. Home
  2. News
  3. ZGNX

Zogenix Announces Date Change for Third Quarter 2020 Financial Results and Conference Call and Webcast to November 9

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
earnings

EMERYVILLE, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it has changed the date of its previously announced earnings release and earnings call. The Company will now report its financial results for the three and nine months ended September 30, 2020 and host a corporate update conference call and webcast after the market close on Monday, November 9, 2020, at 4:30 PM Eastern Time.

Conference Call Details
Monday, November 9, at 4:30 PM Eastern Time / 1:30 PM Pacific Time
Toll Free:877-407-9716
International:201-493-6779
Conference ID:13711927
Webcast:

http://public.viavid.com/index.php?id=141969

About Zogenix
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and received a positive CHMP opinion in Europe for the treatment of seizures associated with Dravet syndrome, a rare, severe childhood onset epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, a different rare childhood-onset epilepsy and another for MT1621, an investigational novel substrate enhancement therapy for the treatment of TK2 deficiency, a rare genetic disorder. MT1621 is being developed through Modis Therapeutics, a Zogenix company.

Zogenix 
Melinda Baker 
Senior Director, Corporate Communications 
+1 (510) 788-8732 | corpcomms@zogenix.com 

Investors 
Brian Ritchie 
Managing Director, LifeSci Advisors LLC 
+1 (212) 915-2578 | britchie@lifesciadvisors.com 

Media 
In Europe: Kerry Lloyd-Jones, Account Director, Porter Novelli
+44 (0) 7949 794 290 | kerry.lloyd-jones@porternovelli.co.uk
In the US: Stefanie Tuck, Vice President, Porter Novelli
+1 (978) 390-1394 | stefanie.tuck@porternovelli.com

Stock ZGNX logo
ZGNX

NASDAQ:ZGNX

ZGNX Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

ZGNX Latest News

Mar 7, 2022
UCB Completes Acquisition of Zogenix, Inc.
Mar 4, 2022
Zogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022
Mar 1, 2022
Immunicom Appoints Jennifer Haldeman as Vice President of Commercial Operations
Feb 28, 2022
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results
Feb 15, 2022
Zogenix Supports New No-Cost Genetic Testing Program with United Mitochondrial Disease Foundation to Improve Diagnosis of Mitochondrial Diseases

ZGNX Stock Data

0
49.18M
0.68%
107.24%
10.57%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Emeryville

About ZGNX

Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company's first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.